United Advisor Group LLC Has $1.11 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

United Advisor Group LLC lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 112.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,394 shares of the biopharmaceutical company’s stock after acquiring an additional 11,307 shares during the quarter. United Advisor Group LLC’s holdings in Bristol-Myers Squibb were worth $1,107,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the company. Greenwood Capital Associates LLC grew its holdings in Bristol-Myers Squibb by 602.5% during the 3rd quarter. Greenwood Capital Associates LLC now owns 37,097 shares of the biopharmaceutical company’s stock worth $1,919,000 after acquiring an additional 31,816 shares during the period. Solitude Financial Services increased its holdings in Bristol-Myers Squibb by 17.1% in the third quarter. Solitude Financial Services now owns 10,310 shares of the biopharmaceutical company’s stock valued at $533,000 after purchasing an additional 1,509 shares during the last quarter. Quintet Private Bank Europe S.A. lifted its stake in Bristol-Myers Squibb by 10.1% in the third quarter. Quintet Private Bank Europe S.A. now owns 60,670 shares of the biopharmaceutical company’s stock valued at $3,139,000 after buying an additional 5,582 shares during the period. PDS Planning Inc boosted its stake in Bristol-Myers Squibb by 14.5% during the 3rd quarter. PDS Planning Inc now owns 5,514 shares of the biopharmaceutical company’s stock worth $285,000 after acquiring an additional 699 shares during the last quarter. Finally, National Pension Service grew its holdings in Bristol-Myers Squibb by 19.1% during the third quarter. National Pension Service now owns 4,672,762 shares of the biopharmaceutical company’s stock valued at $241,769,000 after purchasing an additional 749,696 shares during the period. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BMY. UBS Group lifted their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 9th. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Jefferies Financial Group lifted their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th. Barclays raised their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. Finally, Citigroup downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $75.00 to $55.00 in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $53.00.

Bristol-Myers Squibb Trading Up 2.1 %

NYSE:BMY opened at $55.45 on Tuesday. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $56.20. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The stock’s 50-day simple moving average is $51.41 and its 200 day simple moving average is $46.61.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.00 EPS. On average, analysts forecast that Bristol-Myers Squibb will post 0.83 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.33%. Bristol-Myers Squibb’s dividend payout ratio is currently -66.85%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.